Latest filing published 23 Jan 2024 for Mirati Therapeutics, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Jamie Christensen (senior executive) discloses dealings in Mirati Therapeutics, Inc. to SEC (Form 4). In total, 20 filings cover trades dated from 24 May 2021 to 23 January 2024.
On the market, this insider has only sold: 12 sales, €1.0M in total. Besides market trades, the filings include 7 share grants. Since January 2024: no purchases and 2 sales on the market.
Most recently, on 23 January 2024, the filings show a transaction in Mirati Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
20 of 20 declarations